March 31, 2021
Radiotherapy after breast-conserving surgery for the treatment of ductal carcinoma in situ (DCIS) reduces the risk of ipsilateral breast events without changing survival Between March 18th and 19th, SSO 2021 (International Conference […]
July 15, 2020
New therapeutic option for patients with high-risk HR-positive, HER2-negative breast cancer Abemaciclib in combination with standard adjuvant endocrine therapy (ET) achieved its primary objective in the […]
May 14, 2020
Approval is based on exclusive clinical trial that included patients with active brain metastases On April 17, 2020, the U.S. FDA (US Food and Drug Administration) […]
May 13, 2020
Fast Track is based on the response rate and duration of the response and reinforces the premise that the Trop-2 antigen is an important target to […]
May 8, 2020
This pre-existing resistance mutation was related to a worse outcome in terms of overall survival and recurrence-free survival During the virtual session of the annual conference […]
May 4, 2020
Tazolaparib has shown no OS benefit in patients with advanced/metastatic negative HER2 breast cancer and germline BRCA1 / 2 mutations (gBRCAm) The Overall Survival (OS) results […]
March 31, 2020
According to the manufacturer’s recent statement, the combination of durvalumab and tremelimumab did not lead to an increase in overall survival (OS) in patients undergoing treatment […]
March 25, 2020
Through a phase II study recently published in the journal Lancet Oncology, an AKT inhibitor for the first time demonstrates effectiveness in the metastatic breast cancer […]
February 27, 2020
On February 25, The US Food and Drug Administration (FDA) approved neratinib (Nerlynx®) in combination with capecitabine (Xeloda®) for the treatment of adult patients with advanced […]